Antiviral activity of liquorice powder extract against Varicella zoster virus isolated from Egyptian patients

Chang Gung Medical Journal

Volumn 35, Issue 3, 2012, Pages 231-239

  Shebl, Rania I ^a   Amin, Magdy A ^b   Emad Eldin, Amal ^b   Dajem, Saad M Bin ^c   Mostafa, Amal S ^d   Ibrahim, Essam H ^c,d   Mohamed, Aly F ^a  

^a Holding Company for Biological Products and Vaccines (VACSERA)   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

^c KING KHALID UNIVERSITY   (Saudi Arabia)

^d National Organization for Research and Control of Biologicals   (Egypt)

Author keywords

Antiviral agents; Immunodot; Immunofluorescence; Varicella zoster virus; Virus isolation

Indexed keywords

ACICLOVIR; ALPHA2A INTERFERON; GLYCYRRHIZA EXTRACT;

ANTIVIRAL ACTIVITY; ARTICLE; CHILD; CONCENTRATION RESPONSE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; MALE; MOUSE; NONHUMAN; POWDER; PRESCHOOL CHILD; VARICELLA ZOSTER VIRUS; VERO CELL; VIROGENESIS; VIRUS CULTURE; VIRUS IDENTIFICATION; VIRUS INFECTIVITY; VIRUS ISOLATION;

ANIMALS; ANTIVIRAL AGENTS; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; GLYCYRRHIZA; HERPESVIRUS 3, HUMAN; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PLANT EXTRACTS; VIRUS REPLICATION;

EID: 84863545798     PISSN: 20720939     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Yaghoobi M, Sadeghi-Zadeh M, Naderi-Manesh H, Noori-Daloii M. Varicella Zoster Virus (VZV) origindependent plasmid replication in the presence of the four overlapping cosmids comprising the complete genome of VZV. J Sciences 2004;15:21-6.
2. Kaushik KS, Lahiri KK, Chumber SK, Gupta RM, Kumar S, Kapila K, Karade S. Molecular characterization of clinical varicella-zoster strains from India and differentiation from the oka vaccine strain. Jpn J Infect Dis 2008;61:65-7.
3. Lopez AS, Marin M. Strategies for the control and investigation of varicella outbreaks Manual, 2008. Centers for Disease Control and Prevention. Available from: www.cdc.gov.chickenpox/outbreaks/manual.html.
4. Vonsover A, Leventon-Kriss S, Langer A, Smetana Z, Zaizov R, Potaznick D, Cohen IJ, Gotlieb-Stematsky T. Detection of varicella-zoster virus in lymphocytes by DNA hybridization. J Med Virol 1987;21:57-66.
5. Connie RM, George M. Laboratory identification of significant isolates. Text book of Diagnostic Microbiology. 2nd ed. Philadelphia, USA: WB Saunders Co., 2000:840-1.
6. Marin J, Kese D, Potocnik M, Rogl BM. Laboratory diagnosis of herpesviruses. Dermatovenerologica 2000;9:20-5.
7. Winn W Jr, Allen S, Janda W, Koneman E, Procop G, Schreackenberger P, Woods G, eds. Koneman's Colour Atlas and Textbook of Diagnostic Microbiology. 6th ed. Philadelphia: Lippincott Williams and Wilkins, 2006:859-940.
8. Gross G, Doerr H. Herpes Zoster: Recent Aspects of Diagnosis and Control. New York: Karger Publishers, 2006:15-8.
9. Breuer J, Whitley R. Varicella zoster virus: natural history and current therapies of varicella and herpes zoster. Herpes 2007;14 suppl 2:25-9.
10. Arvin AM. Varicella-zoster virus. Clin Microbiol Rev 1996;9:361-81.
11. Saint-Leger E, Caumes E, Breton G, Douard D, Saiag P, Huraux JM, Bricaire F, Agut H, Fillet AM. Clinical and virologic characterization of acyclovir-resistant varicellazoster viruses isolated from 11 patients with acquired immunodeficiency syndrome. Clin Infect Dis 2001;33: 2061-7.
12. Aoki F, Nakagawa K, Tanaka A, Matsuzaki K, Arai N, Mae T. Determination of glabridin in human plasma by solid-phase extraction and LC-MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci 2005;828:70-4.
13. Fukai T, Satoh K, Nomura T, Sakagami H. Preliminary evaluation of antinephritis and radical scavenging activities of glabridin from Glycyrrhiza glabra. Fitoterapia 2003;74:624-9.
14. Biondi DM, Rocco C, Ruberto G. Dihydrostilbene derivatives from Glycyrrhiza glabra leaves. J Nat Prod 2005;68:1099-102.
15. Cherng JM, Lin HJ, Hung MS, Lin YR, Chan MH, Lin JC. Inhibition of nuclear factor kappaB is associated with neuroprotective effects of glycyrrhizic acid on glutamateinduced excitotoxicity in primary neurons. Eur J Pharmacol 2006;547:10-21.
16. Zhang Q, Ye M. Chemical analysis of the Chinese herbal medicine Gan-Cao (licorice). J Chromatogr A 2009;1216: 1954-69.
17. Acharya SK, Dasarathy S, Tandon A, Joshi YK, Tandon BN. A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J Med Res 1993;98:69-74.
18. Tanahashi T, Mune T, Morita H, Tanahashi H, Isomura Y, Suwa T, Daido H, Gomez-Sanchez CE, Yasuda K. Glycyrrhizic acid suppresses type 2 11 beta-hydroxysteroid dehydrogenase expression in vivo. J Steroid Biochem Mol Biol 2002;80:441-7.
19. Fujisawa Y, Sakamoto M, Matsushita M, Fujita T, Nishioka K. Glycyrrhizin inhibits the lytic pathway of complement-possible mechanism of its anti-inflammatory effect on liver cells in viral hepatitis. Microbiol Immunol 2000;44:799-804.
20. Ito A, Hayashi N, Katayama K, Hagiwara H, Kasahara A, Kashiwagi T, Yoshihara H, Fusamoto H, Kamada T. Effect of glycyrrhizin on viral replication and quasispecies in patients with type C chronic hepatitis. Int Hepatol Commun 1997;6:233-8.
21. Cinatl J, Morgenstern B, Bauer G Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet 2003;361:2045-6.
22. Fu B, Liu J, Li H, Li L, Lee FS, Wang X. The application of macroporous resins in the separation of licorice flavonoids and glycyrrhizic acid. J Chromatogr A 2005;1089:18-24.
23. Joseph LW, Thomas HW. Varicella-zoster virus. Diagnostic procedures for viral, rickettsial and chlamydial infections. 6th ed. American Public Health Association, 1994:379-406.
24. Arvin AM. Varicella-zoster virus. In: Knipe DM, Howley PM, eds. Fields Virology, Vol 2. 4th ed. Philadelphia, Pa: Lippincott Williams & Wilkins, 2001:2731-67.
25. Abed El-Gaied HA, Hashem A, El-tayeb O, Mohamed AF. Evaluation of Inactivation efficacy of Sabin polio virus using different inactivating agents and its related immunogenicity post nano and microcappsulation. JMM 2010;1:114-22.
26. Takasuka N, Fujii H, Takahashi Y, Kasai M, Morikawa S, Itamura S, Ishii K, Sakaguchi M, Ohnishi K, Ohshima M, Hashimoto S, Odagiri T, Tashiro M, Yoshikura H, Takemori T, Tsunetsugu-Yokota Y. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol 2004;16:1423-30.
27. Schutzbank T, Robyn M. Immunofluorescence. In: Specter S, Hodinka RL, Young SA, eds. Clinical Virology Manual, 3rd ed. Washington, DC: ASM Press, 2000:77-88.
28. Abendroth A, Morrow G, Cunningham AL, Slobedman B. Varicella-zoster virus infection of human dendritic dells and transmission to T Cells: implications for virus dissemination in the host. J Virol 2001;75:6183-92.
29. Kaufmann SH, Ewing CM, Shaper JH. The erasable Western blot. Anal Biochem 1987;161:89-95.
30. Steven S, Richard LH, Stephen AY. Laboratory Procedures. In: Specter S, Hodinka RL, Young SA, eds. Clinical Virology Manual. 3rd ed. Washington, DC: ASM Press, 2000:69-152.
31. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hygiene 1928;27:493-7.
32. Grose C, Brunel PA. Varicella-zoster virus: isolation and propagation in human melanoma cells at 36 and 32 degrees C. Infect Immun 1978;19:199-203.
33. Finter NB. Dye uptake methods for assessing viral cytopathogenicity and their application to interferon assays. J Gen virol 1969;5:419-27.
34. Vijayan P, Raghu C, Ashok G, Dhanaraj SA, Suresh B. Antiviral activity of medicinal plants of Nilgiris. Indian J Med Res 2004;120:24-9.
35. Taylor JL, Casey MS, O'Brien WJ. Synergistic antiherpes virus activity of acyclovir and interferon in human corneal stromal cells. Invest Ophthalmol Vis Sci 1990;30:365-70.
36. Shin HJ, Cho MS, Jung SY, Kim HI, Im KI. In vitro cytotoxicity of Acanthamoeba spp. isolated from contact lens containers in Korea by crystal violet staining and LDH release assay. Korean J Parasitol 2000;38:99-102.
37. Harada S. The broad anti-viral agent glycyrrhizin directly modulates the fluidity of plasma membrane and HIV-1 envelope. Biochem J 2005; 392(Pt 1):191-9.
38. Wutzler P. Antiviral therapy of herpes simplex and varicella-zoster virus infections. Intervirology 1997;40:343-56.
39. Weller TH. Varicella-herpes zoster virus. Viral Infections of Humans: Epidemiology and Control. In: Evans AS, Kaslow RA, eds. Viral Infections of Humans: Epidemiology and Control. New York: Plenum Press, 1997:865-92.
40. Loparev V, Martro E, Rubtcova E, Rodrigo C, Piette JC, Caumes E, Vernant JP, Schmid DS, Fillet AM. Toward universal varicella-zoster virus (VZV) genotyping: diversity of VZV strains from France and Spain. J Clin Microbiol 2007;45:559-63.
41. Ozaki T, Ichikawa T, Matsui Y, Kondo H, Nagai T, Asano Y, Yamanishi K, Takahashi M. Lymphocyte-associated viremia in varicella. J Med Virol 1986;19:249-53.
42. Schmutzhard J, Merete Riedel H, Zweygberg Wirgart B, Grillner L. Detection of herpes simplex virus type 1, herpes simplex virus type 2 and varicella-zoster virus in skin lesions. Comparison of real-time PCR, nested PCR and virus isolation. J Clin Virol 2004;29:120-6.
43. Gerna G, Chambers RW. Varicella-zoster plaque assay and plaque reduction neutralization test by the immunoperoxidase technique. J Clin Microbiol 1976;4: 437-42.
44. O'Neill HJ, Russell JD, Wyatt DE, McCaughey C, Coyle PV. Isolation of viruses from clinical specimens in microtitre plates with cells inoculated in suspension. J Virol Methods 1996;62:169-78.
45. Levin MJ, Leventhal S, Masters HA. Factors influencing quantitative isolation of varicella-zoster virus. J Clin Microbiol 1984;19:880-3.
46. Ozaki T, Kajita Y, Namazue J, Yamanishi K. Isolation of varicella-zoster virus from vesicles in children with varicella. J Med Virol 1996;48:326-8.
47. Moretti F, Uberti-Foppa C, Quiros-Roldan E, Fanti L, Lillo F, Lazzarin A. Oesophagobronchial fistula caused by varicella zoster virus in a patient with AIDS: a unique case. J Clin Pathol 2002;55:397-8.
48. Rawlinson WD, Dwyer DE, Gibbons VL, Cunningham AL. Rapid diagnosis of varicella-zoster virus infection with a monoclonal antibody based direct immunofluorescence technique. J Virol Methods 1989;23:13-8.
49. Meqdam MM, Todd D, Al-Abosi M. Detection of herpes simplex and varicella-zoster viruses in clinical specimens using direct immunofluorescence and cell culture assays. Microbios 2001;105:111-8.
50. Leonardi MS, Gazzara D, Zummo S, Fattal-German M, Bizzini B, Mastroeni P. A dot-ELISA for the detection of IgG antibodies to mumps and varicella viruses. J Clin Lab Anal 1990;4:165-9.
51. Baba M, Shigeta S. Antivrial activity of glycrrhizin against varicella-zoster virus in vitro. Antiviral Res 1990;7:99-107.
52. Yarnell E, Abascal K. Herbs for treating Herpes Zoster infections. Alternative and Complementary Therapies 2005;11:131-4.
53. Chia-Chi K, Anne S, Arvin A. The anti-viral effects of interferon-ααon varicella-zoster virus (VZV). Clinical Immunology 2006;119:181-3.
54. Muller-Doblies D, Ackermann M, Metzler A. In vitro and in vivo detection of Mx gene products in bovine cells following stimulation with alpha/beta interferon and viruses. Clin Diagn Lab Immunol 2002;9:1192-9.